ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO

被引：0
|
作者：
Liang, Muh-Lii [1 ]
Hsieh, Tsung-Han [2 ]
Wong, Tai-Tong [3 ]
机构：
[1] Mackay Mem Hosp, Dept Neurosurg, Taipei, Taiwan
[2] Taipei Med Univ, Off Human Res, Joint Biobank, Taipei, Taiwan
[3] Taipei Med Univ Hosp, Dept Neurosurg, Taipei, Taiwan
来源：
NEURO-ONCOLOGY | 2020年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MODL-16
引用
收藏
页码：414 / 414
页数：1
相关论文
共 50 条
  • [41] Discovery of dual CDK4/6 and BRD4 inhibitor as apoptosis and autophagy inducers against NSCLC in vitro and in vivo
    Zhang, Yonglei
    Luo, Zhongwen
    Jiang, Yuhan
    Zheng, Long
    Ma, Liangliang
    Zheng, Yiwei
    Zou, Meiting
    Kong, Lingyi
    Wang, Xiaobing
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 290
  • [42] LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.
    Dempsey, Jack A.
    Chan, Edward M.
    Burke, Teresa F.
    Beckmann, Richard P.
    CANCER RESEARCH, 2013, 73 (08)
  • [43] Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
    Goetz, M. P.
    Beeram, M.
    Beck, T.
    Conlin, A. K.
    Dees, E. C.
    Dickler, M. N.
    Helsten, T. L.
    Conkling, P. R.
    Edenfield, W. J.
    Richards, D. A.
    Turner, P. K.
    Cai, N.
    Chan, E. M.
    Pant, S.
    Becerra, C. H.
    Kalinsky, K.
    Puhalla, S. L.
    Rexer, B. N.
    Burris, H. A.
    Tolaney, S. M.
    CANCER RESEARCH, 2016, 76
  • [44] The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing's sarcoma
    Dowless, Michele
    Lowery, Caitlin
    Renschler, Matthew
    Blosser, Wayne
    Stephens, Jennifer
    Flack, Robert
    Credille, Kelly
    Chen, Mia
    Dorsey, Frank
    Sams, Lillian
    Ebert, Philip
    Olsen, Jonathan
    Shackleford, Terry
    Houghton, Peter
    Stancato, Louis
    CANCER RESEARCH, 2018, 78 (19)
  • [45] CDK4/6 inhibitor abemaciclib induces atypical cell-death with vacuolar formation by impairing lysosomal functions
    Hino, Hirotsugu
    Kazama, Hiromi
    Moriya, Shota
    Takano, Naoharu
    Hiramoto, Masaki
    Miyazawa, Keisuke
    CANCER SCIENCE, 2021, 112 : 900 - 900
  • [46] METRONOMIC INTRATHECAL DELIVERY OF CDK4/6 INHIBITORS IN PRECLINICAL MODELS OF PEDIATRIC BRAIN TUMORS
    Guadix, Sergio
    Martin, Brice
    Laramee, Madeline
    Dahmane, Nadia
    Thomas, Craig
    Souweidane, Mark
    NEURO-ONCOLOGY, 2022, 24 : 169 - 169
  • [47] An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
    James, Alexander D.
    Schiller, Hilmar
    Marvalin, Cyrille
    Jin, Yi
    Borell, Hubert
    Roffel, Ad F.
    Glaenzel, Ulrike
    Ji, Yan
    Camenisch, Gian
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2020, 8 (03):
  • [48] CDK4/6 INHIBITION WITH ABEMACICLIB SENSITIZES INTRACRANIAL TUMORS TO CHECKPOINT BLOCKADE IN PRE-CLINICAL MODELS OF BRAIN METASTASIS
    Nayyar, Naema
    De Sauvage, Magali
    Sullivan, Emily
    Chuprin, Jane
    Yamazawa, Erika
    Michael, Brehm
    Brastianos, Priscilla
    NEURO-ONCOLOGY, 2022, 24 : 98 - 98
  • [49] An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations
    Kim, K. H.
    Park, C.
    Beom, S. -H
    Kim, M. H.
    Kim, C. G.
    Kim, H. R.
    Jung, M.
    Shin, S. J.
    Rha, S. Y.
    Kim, H. S.
    ESMO OPEN, 2025, 10 (02)
  • [50] Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib
    Bouchekioua-Bouzaghou, Katia
    Lenihan, Catherine
    Shia, Alice
    Wilkes, Edmund
    Casado-Izquierdo, Pedro
    Cutillas, Pedro
    Schmid, Peter
    CANCER RESEARCH, 2016, 76
12345